Abstract 796P
Background
LGSOC is a rare disease. Few data of large size have been published.
Methods
We conducted a multicenter retrospective analysis of LGSC patients selected from the French Epidemiological Strategy and Medical Economics Ovarian Cancer database between 2000 and 2019. This database includes all ovarian cancer pts treated in 18 French Comprehensive Cancer Centers. The main objective was to describe the management of these patients. Secondary objectives were to analyse progression-free survival (PFS) and overall survival (OS) and prognostic factors in the stage III/IV population.
Results
Out of the 13032 pts, 230 (1.8%) with a confirmed diagnosis of stage III (n=171)/IV (n=59) LGSOC were identified. Median age at diagnosis was 55.5y (19.8-88.2). 128 (55.6%) pts had primary debulking surgery (PDS) and 35 (15.2%) neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS). 49 (21.3%) pts did not have debulking surgery and 18 (7.9%) patients had surgery after 6 courses of NACT. 223 pts (97.0%) received platinum-based chemotherapy (PBC) including bevacizumab (Bev) for 79 pts (34.3%). Endocrine therapy maintenance was given in 27 pts. After a median follow up of 73.6m [69.9-80.0], median OS was 93.4m (95%CI [71.2-176.9]) in the whole population. Median OS according to timing of surgery was 146.0m (95%CI [110.4-NR]) with PDS vs. 75.5m (95%CI [48.7-Not Reached]) with NACT-IDS vs. 61.8m (95%CI [42.4-NR]) with 6 courses of NACT and closing surgery. Patients not candidate for surgery received PBC (n=49) +/-Bev (14/49) +/- maintenance endocrine therapy (13/49). With a median follow-up of 64.6m (38.6-93.6), median PFS and OS were 15.9m (95%CI [13.4-20.6]) and 38.0 m (95%CI [33.0-65.0]) respectively. OS multivariable analyses are shown in the table.
Table: 796P
HR | 95%CI | p value | |
Initial FIGO stage | |||
III | |||
IV | 2.40 | 1.48,3.91 | <0.001 |
Timing of surgery | |||
Primary debulking surgery | |||
Interval debulking surgery or closing surgery | 1.93 | 1.13, 3.34 | 0.018 |
No surgery | 2.65 | 1.50;4.68 | <0.001 |
Age (continuous variable) | 1.01 | 1.00, 1.03 | 0.038 |
Bevacizumab first line | |||
No | |||
Yes | 0.82 | 0.51, 1.30 | 0.393 |
Conclusions
In this large size population of advanced LGSOC, FIGO IV stage, absence of PDS and age are associated with poorer OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Pautier: Financial Interests, Personal, Advisory Board, 2015 , 2022 : PharmaMar; Financial Interests, Institutional, Advisory Board, 2020 : Roche, Clovis; Financial Interests, Institutional, Advisory Board, 2021: AstraZeneca; Financial Interests, Personal, Advisory Board, 2019-2020: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, 2018-2019: Roche; Financial Interests, Institutional, Advisory Board, 2022 : MSD; Financial Interests, Personal and Institutional, Research Grant: PharmaMar; Financial Interests, Research Grant: ONXEO. F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, Ipsen, BMS, Bayer, Eisai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Coordinating PI: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Other, travel: MSD, GSK. T. De La Motte Rouge: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, GSK, Clovis Oncology, Roche, Mylan, Tesaro, Gilead, Sanofi; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Research Grant: Novartis, Pfizer, MSD, Seagen; Financial Interests, Institutional, Local PI: Roche, AstraZeneca, GSK, MSD, Pfizer, Netris Pharma; Non-Financial Interests, Advisory Role: French National Cancer Institute, Unicancer; Non-Financial Interests, Principal Investigator: Arcagy; Non-Financial Interests, Other, Co-Principal Investigator: Unicancer. R. Sabatier: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Invited Speaker: EISAI, Clovis Oncology; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Other, Travel fees: MSD, Novartis; Non-Financial Interests, Other, Congress fees: GSK. P. Colombo: Financial Interests, Personal, Invited Speaker: GSK, MSD. C. Pomel: Financial Interests, Personal, Advisory Board: Roche, Roche, GSK, PharmaMar, MSD; Financial Interests, Personal, Invited Speaker: Roche, GSK, PharmaMar. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. L. Gladieff: Financial Interests, Personal, Other, Congress funding: Viatris, Roche; Financial Interests, Institutional, Invited Speaker: MSD, Clovis, GSK, Eisai; Financial Interests, Institutional, Advisory Board: Clovis, GSK; Financial Interests, Personal, Invited Speaker: AstraZeneca. J. Frenel: Financial Interests, Personal, Advisory Board: Pfizer, Novocure, Pierre Fabre, Eisai, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: GSK, Amgen; Financial Interests, Institutional, Advisory Board: Exactscience, Lilly, Daiichi Sankyo, AstraZeneca, Clovis Oncology; Financial Interests, Institutional, Invited Speaker: Novartis, MSD; Financial Interests, Invited Speaker: AstraZeneca, Seagen, MSD, Daiichi Sankyo; Non-Financial Interests, Principal Investigator: Novartis, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11